Advertisement

Foot-and-mouth disease and beyond: vaccine design, past, present and future

  • F. Brown
Chapter
Part of the Archives of Virology. Supplementa book series (ARCHIVES SUPPL, volume 15)

Summary

The first experimental vaccines against foot-and-mouth disease were made in 1925 by Vallee, Carre and Rinjard using formaldehyde inactivation of tongue tissue from cattle infected with the virus. This method was essentially unaltered until the late 1940s when the important experiments by Frenkel in Holland showed that the quantities of virus required for vaccine production could be obtained from fragments of tongue epithelium incubated in vitro following infection with the virus. This major step made possible the comprehensive vaccination programmes which followed in Western Europe and which, in turn, resulted in the elimination of the disease from that part of the world by 1989. This spectacular success has led many to question whether other kinds of vaccine are required to control the disease worldwide. Such reservations ignore the danger to the environment associated with the growth of large amounts of virus. This can never be a zero-risk situation. Consequently, a vaccine which is not based on infectious virus as starting material has many attractions from safety considerations alone. In addition, a vaccine based on more fundamental considerations would not only be more aesthetically satisfying but could possibly provide an understanding at the molecular level of antigenic variation, still a problem in the control of the disease.

The advances in our knowledge of the structure of the virus and the fragments which elicit a protective immune response now allow us to envisage a vaccine which does not require infectious virus and which protects against the multiple serotypes of the agent. Since antigenic variation is still a major problem in the control of the disease by vaccination, such a product would have important advantages over the current vaccines.

Keywords

Disease Virus Virus Particle Antigenic Variation Peptide Vaccine Tongue Epithelium 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Acharya R, Fry E, Stuart D, Fox G, Rowlands DJ, Brown F (1989) The three-dimensional structure of foot-and-mouth disease virus at 2.9 Å resolution. Nature 337: 709–716PubMedCrossRefGoogle Scholar
  2. 2.
    Bachrach HL, Moore DM, McKercher PD, Polatnick J (1975) Immune and antibody responses to an isolated capsid protein of foot-and-mouth disease virus. J Immunol 115: 1636–1641PubMedGoogle Scholar
  3. 3.
    Bahnemann HG (1975) Binary ethyleneimine as an inactivant for foot-and-mouth disease virus and its application for vaccine production. Arch Virol 47: 47–56PubMedCrossRefGoogle Scholar
  4. 4.
    Beck E, Strohmaier K (1987) Subtyping of European foot-and-mouth disease virus strains by nucleotide sequence determination. J Virol 61: 1621–1629PubMedGoogle Scholar
  5. 5.
    Bedson SP, Maitland HB, Burbury YM (1927) Foot-and-Mouth Disease Research Committee, 2nd Report. HMSO, London, p 99Google Scholar
  6. 6.
    Bittle JL, Houghten RA, Alexander H, Shinnick TM, Sutcliffe JG, Lerner RA, Rowlands DJ, Brown F (1982) Protection against foot-and-mouth disease by immunization with a chemically synthesized peptide predicted from the viral nucleotide sequence. Nature 298: 30–33PubMedCrossRefGoogle Scholar
  7. 7.
    Braind J-P, Benkirane N, Guichard G, Newman JFE, Van Regenmortel MHV, Brown F, Müller S (1997) A retro-inverso peptide corresponding to the GH loop of foot-and-mouth disease virus elicits high levels of long-lasting protective neutralising antibodies. Proc Natl Acad Sci USA 94: 12 445–12 550Google Scholar
  8. 8.
    Brown F (1994) The importance of antigenic variation in vaccine design. Arch Virol [Suppl] 9: 1–8Google Scholar
  9. 9.
    Brown F, Cartwright B (1963) Purification of radio-active foot-and-mouth disease virus. Nature 31: 1168–1170CrossRefGoogle Scholar
  10. 10.
    Brown F, Hyslop NSt.G, Crick J, Morrow AW (1963) The use of acetylethyleneimine in the production of inactivated foot-and-mouth vaccines. J Hyg 61: 337–344CrossRefGoogle Scholar
  11. 11.
    Brown F, Crick J (1959) Application of agar gel diffusion analysis to a study of the antigenic structure of inactivated vaccines prepared from the virus of foot-and-mouth disease. J Immunol 82: 444–447PubMedGoogle Scholar
  12. 12.
    Curry S, Abrams CC, Fry E, Crowther JC, Belsham GJ Stuart DI, King AM (1995) Viral RNA modulates the acid sensitivity of foot-and-mouth disease virus capsids. J Virol 69: 430–438PubMedGoogle Scholar
  13. 13.
    DenoyaCD, ScodellerEA, VasquezC, La Torre JL (1978) Foot-and-mouth disease virus: II. Endoribonuclease activity within purified virions. Virology 89: 67–74PubMedCrossRefGoogle Scholar
  14. 14.
    DiMarchi R, Brooke G, Gale C, Cracknell V, Doel T, Mowat N (1986) Protection of cattle against foot-and-mouth disease by a synthetic peptide. Science 232: 639–641CrossRefGoogle Scholar
  15. 15.
    Francis MJ, Hastings GZ, Syred AD, McGinn B, Brown F, Rowlands DJ (1987) Non-responsiveness to a foot-and-mouth disease virus peptide overcome by addition of foreign helper T-cell determinants. Nature 330: 168–170PubMedCrossRefGoogle Scholar
  16. 16.
    Frenkel HS (1930) La culture du virus de la fievre aphteuse sur 1’epithelium de la langue des bovides. Bull Off Int Epizool 28: 155–162Google Scholar
  17. 17.
    Hecke F (1931) Zuechtungsversuche des Maul-und-Klauenseuchevirus in Gewebekulturen. Zbl Bakt Parasitk I 116: 386–414Google Scholar
  18. 18.
    Galloway IA, Henderson WM, Brooksby JB (1948) Strains of the virus of foot-and-mouth disease recovered form outbreaks in Mexico. Proc Soc Exp Biol Med 69: 57–63PubMedGoogle Scholar
  19. 19.
    Geysen HM, Meloen RH, Barteling SJ (1984) Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid. Proc Natl Acad Sci USA 81: 3998–4002PubMedCrossRefGoogle Scholar
  20. 20.
    Graves JH (1963) Formaldehyde inactivation of foot-and-mouth disease virus as applied to vaccine preparation. Am J Vet Res 24: 1 131–1135Google Scholar
  21. 21.
    Grigera PR, Tisminetzky SG, Lebendiker MB, Periolo OH, La Torre JL (1988) Presence of a 43-KDa host-cell polypeptide in purified aphthovirions. Virology 165: 584–588PubMedCrossRefGoogle Scholar
  22. 22.
    King AMQ, Underwood BO, McCahon D, Newman JWI, Brown F (1981) Biochemical identification of viruses causing the 1981 outbreaks of foot-and-mouth disease in the U.K. Nature 293: 479–480PubMedCrossRefGoogle Scholar
  23. 23.
    Kleid DG, Yansura D, Small B, Dowbenko D, Moore DM, Grubman MJ, McKercher PD, Morgan DO, Robertson BH, Bachrach HL (1981) Cloned viral protein vaccine for foot-and-mouth disease; responses in cattle and swine. Science 214: 1125–1129PubMedCrossRefGoogle Scholar
  24. 24.
    Laporte J, Grosclaude J, Wantyghem J, Bernard S, Rouze P (1973) Neutralisation en culture cellulaire du pouvior infectieux du virus de la fievre aphteuse par des serum provenant de porcs immunises a l’aide d’une proteine virale purifiee. C R Acad Sci 276: 3399–3401Google Scholar
  25. 25.
    Loeffler F, Frosch P (1898) Berichte der Kommission zur Erforschung der Maul-und-Klauenseuche bei dem Institut fur Infektionskrankheiten in Berlin. Centralblatt Bakt I Abt Orig 23: 371–391Google Scholar
  26. 26.
    Maitland MC, Maitland HB (1931 ) Cultivation of foot-and-mouth disease virus. J Comp Pathol Ther 44: 106–113Google Scholar
  27. 27.
    Mezencio JMS, Babcock GD, Kramer E, Brown F (1999) Evidence for the persistence of foot-and-mouth disease virus in pigs. Vet J 157: 213–217PubMedCrossRefGoogle Scholar
  28. 28.
    Moosbrugger GA (1948) Rechserches experimentales sur la fievre aphteuse. Schweiz Arch Tierheilk 90: 179–198Google Scholar
  29. 29.
    Newman JFE, Brown F (1997) Foot-and-mouth disease virus and poliovirus particles contain proteins of the replication complex. J Virol 71: 7657–7662PubMedGoogle Scholar
  30. 30.
    Newman, JFE, Piatti PG, Gorman BM, Burrage TG, Ryan MD, Flint M, Brown F (1994) Foot-and-mouth disease virus particles contain replicase protein 3D. Proc Natl Acad Sci USA 91: 733–737PubMedCrossRefGoogle Scholar
  31. 31.
    Pfaff E, Mussgay M, Bohm HO, Schulz GE, Schaller H (1982) Antibodies against a preselected peptide recognizes and neutralize foot-and-mouth disease virus. Eur Mol Biol Organ 1: 869–874Google Scholar
  32. 32.
    Parry N, Fox G, Rowlands D, Brown F, Fry E, Acharya R, Logan D, Stuart D (1990) Serological and structural evidence for a novel mechanism of antigenic variation in foot-and-mouth disease virus. Nature 347: 569–572PubMedCrossRefGoogle Scholar
  33. 33.
    Rosenbusch CT, Decamps A, Gelormini N (1948) Intradermal foot-and-mouth disease vaccine. Results obtained from the first million head of cattle vaccinated. J Am Vet Med Assoc 112: 45–47PubMedGoogle Scholar
  34. 34.
    Rowlands DJ, Clarke BE, Carroll AR, Brown F, Nicholson BH, Bittle JL, Houghten RA, Lerner RA (1983) Chemical basis of antigenic variation in foot-and-mouth disease virus. Nature 306: 694–697PubMedCrossRefGoogle Scholar
  35. 35.
    Rowlands DJ, Sangar DV, Brown F (1972) Stabilizing the immunizing antigen of foot-and-mouth disease virus by fixing with formaldehyde. Arch Ges Virusforsch 39: 274–283PubMedCrossRefGoogle Scholar
  36. 36.
    Salt JS (1993) The carrier state in foot-and-mouth disease — an immunological review. Br Vet J 149: 207–223PubMedCrossRefGoogle Scholar
  37. 37.
    Strohmaier K, Franze R, Adam K-H (1982) Localisation and characterisation of the antigenic portion of the foot-and-mouth disease virus protein. J Gen Virol 59: 295–306PubMedCrossRefGoogle Scholar
  38. 38.
    Taboga O, Tami C, Carrillo E, Nunez JI, Rodriguez A, Saiz JC, Blanco E, Valero M-L, Roig A, Camarero JA, Andreu D, Mateu MG, Giralt E, Domingo E, Sobrino F, Palma EL (1997) A large-scale evaluation of peptide vaccines against foot-and-mouth disease: Lack of solid protection in cattle and isolation of escape mutants. J Virol 71: 2606–2614PubMedGoogle Scholar
  39. 39.
    Twomey T, France LL, Hassard S, Burrage TG, Newman JFE, Brown F (1995) Characterization of an acid-resistant mutant of foot-and-mouth disease virus. Virology 206: 69–75PubMedCrossRefGoogle Scholar
  40. 40.
    Vallee H, Carre H (1922) Sur la pluralitc du virus aphteux. C R Acad Sci 174: 1498–1500Google Scholar
  41. 41.
    van Lierop MJ, Wagenaar JP, van Noort JM, Hensen EJ (1995) Sequences derived from the highly antigenic VP1 region 140 to 160 of foot-and-mouth disease virus do not prime for a bovine T-cell response against intact virus. J Virol 69: 4511–4514PubMedGoogle Scholar
  42. 42.
    Waldmann O, Trautwein K (1926) Experimentelle Untersuchungen über die Pluralität des Maul-und Klauenseuche Virus. Berl Tierarztl Wochenschr 42: 569–571Google Scholar
  43. 43.
    Wild TF, Burroughs JN, Brown F (1969) Surface structure of foot-and-mouth disease virus. J Gen Virol 4: 313–320PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 1999

Authors and Affiliations

  • F. Brown
    • 1
  1. 1.Plum Animal Disease CenterGreenportUSA

Personalised recommendations